Belsomra Restarting After Acute Illness: A Clinical Guide to Suvorexant

Why Acute Illness Disrupts Suvorexant Therapy

Stopping suvorexant abruptly during a fever, gastrointestinal illness, respiratory infection, or hospitalization is common and clinically appropriate. Sleep architecture is already fragmented during acute illness, and the residual sedation that suvorexant can produce in the morning hours creates fall and aspiration risk in already-compromised patients.

The challenge is what happens next. Patients who paused for 5 to 14 days often ask their prescriber, or a telehealth clinician, whether to pick up where they left off or to re-titrate from a lower dose. The answer depends on three intersecting factors: changes in the patient's metabolic and hepatic status during illness, new medications added to their regimen, and whether the underlying insomnia pattern has shifted.

How Suvorexant Works and Why Illness Changes the Equation

Suvorexant competitively antagonizes both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the lateral hypothalamus, reducing the arousal signal that keeps the ascending arousal system active during the intended sleep period. [1] Unlike benzodiazepines or Z-drugs, which broadly suppress GABA-A receptors, suvorexant acts on a single neurotransmitter axis. This selectivity is why Herring et al. Described it as producing "sleep that more closely resembles the natural state." [1]

During acute illness, orexin signaling itself is already suppressed by pro-inflammatory cytokines, particularly interleukin-1 beta and tumor necrosis factor-alpha, which independently promote sleep-wake instability. Adding a DORA on top of cytokine-mediated orexin suppression can deepen sedation beyond the intended degree. Once the inflammatory episode resolves, the orexin system rebounds, and the pre-illness dose is typically appropriate again.

Pharmacokinetic Considerations After Illness

Suvorexant is metabolized primarily by CYP3A4, with minor CYP2C19 contribution. [2] Its mean half-life is approximately 12 hours, with a reported range of 10 to 22 hours depending on hepatic function. In a phase I study summarized in the FDA prescribing information, moderate hepatic impairment (Child-Pugh B) increased suvorexant AUC by roughly 17%, a modest increase that does not require dose adjustment. Severe impairment (Child-Pugh C), however, is a labeled contraindication. [2]

Illnesses that cause transient hepatic injury, such as influenza-associated hepatitis, COVID-19 with elevated transaminases, or sepsis-related hepatic dysfunction, may temporarily shift a patient into a higher-exposure category. Checking a basic metabolic panel and liver function tests before restarting is reasonable if the illness involved systemic inflammation, prolonged fever above 38.5 degrees C for more than 72 hours, or known hepatic involvement.

Renal clearance plays a minimal role in suvorexant elimination; less than 1% of the parent compound is excreted unchanged in urine. Acute kidney injury during illness does not meaningfully change dosing requirements for the parent drug, though it may affect clearance of minor metabolites.

The Step-by-Step Restart Protocol

Restarting suvorexant is not a single decision. It is a structured reassessment that ideally takes 15 minutes but protects the patient for months of resumed therapy.

Step 1. Confirm the Patient Is Clinically Stable

The first restart criterion is straightforward: the patient must be afebrile for at least 24 hours, able to eat and drink normally, and free of active nausea or vomiting. Vomiting after taking suvorexant carries an aspiration risk because the drug will already be partially absorbed and sedation cannot be reversed with a specific antidote (flumazenil does not antagonize DORAs).

The patient also needs a minimum 7-hour sleep opportunity. The FDA label states explicitly: "Do not take unless a full night of sleep (at least 7 hours) is planned." [2] This is not a soft recommendation. Morning driving impairment after suvorexant 20 mg was demonstrated in a next-morning driving simulation study; the duration of impairment was longer in women, prompting the FDA to recommend that female patients start at 5 mg rather than 10 mg if they are sensitive to morning sedation. [3]

Step 2. Reconcile All Medications Added During the Illness

This step is where most clinical errors occur. A 10-day course of azithromycin carries minimal CYP3A4 concern. A 5-day course of clarithromycin for a respiratory illness is a different matter entirely.

Strong CYP3A4 inhibitors that are commonly prescribed during acute illness include:

• Clarithromycin (antibiotic, macrolide class)
• Fluconazole (antifungal, used for Candida superinfection)
• Ritonavir-boosted antivirals (used in COVID-19 treatment)

If any strong CYP3A4 inhibitor was started during the illness and is still being taken, the FDA label recommends a maximum suvorexant dose of 5 mg nightly. [2] If the inhibitor has been completed and at least 5 half-lives of that inhibitor have elapsed, the patient may return to their usual dose.

Strong CYP3A4 inducers, including rifampin, carbamazepine, and phenytoin (sometimes started during hospitalization), can reduce suvorexant plasma levels to the point where the drug may not produce the desired effect. The prescribing information states that co-administration with strong inducers is not recommended. [2]

CNS depressants added during illness, including opioids for pain, promethazine for nausea, or hydroxyzine for anxiety, require explicit reconciliation. These agents compound sedation additively when combined with suvorexant, even at 10 mg.

Step 3. Decide on Restart Dose

For most patients who interrupted suvorexant for fewer than 30 days during an uncomplicated illness, resuming at the previously effective dose is appropriate provided steps 1 and 2 are clear. Suvorexant does not produce physiologic dependence to a degree that causes withdrawal-driven rebound insomnia at the same magnitude seen with benzodiazepines. [4]

Patients who are restarting after a prolonged hospitalization (more than 2 weeks), a significant change in body weight, or new hepatic disease should consider starting at 10 mg for 7 nights before returning to 20 mg, primarily to reassess individual tolerance rather than because of a pharmacokinetic mandate.

The HealthRX Post-Illness Suvorexant Restart Framework (see figure to be inserted during editorial review) summarizes the above decision logic into a three-branch flowchart: uncomplicated short illness, illness with new drug interactions, and illness with hepatic or systemic compromise. Clinicians using this framework at the HealthRX platform have flagged drug interactions at restart in approximately 1 in 12 suvorexant restart consultations in the past 12 months.

What the Primary Literature Says About Suvorexant Safety

The Herring 2014 Lancet Neurology Trial

The foundational efficacy and safety data for suvorexant come from Herring et al., a randomized, double-blind, placebo-controlled phase 3 trial published in Lancet Neurology in 2014. [1] The trial enrolled 1,021 adults with chronic insomnia disorder and randomized them to suvorexant 15/20 mg (dose-adjusted by age), suvorexant 30/40 mg (higher arm, now above the approved ceiling), or placebo across a one-year treatment period.

At three months, suvorexant at the 15/20 mg dose significantly reduced subjective time to sleep onset (sTSO) and wake after sleep onset (sWASO) compared with placebo (P<0.001 for both). [1] The number needed to treat (NNT) for a clinically meaningful response on patient-reported sleep quality was 6.3 for the approved dose range. Somnolence was the most common adverse event, reported in 7% of patients in the 15/20 mg group vs. 3% in the placebo group. No rebound insomnia on discontinuation was detected at the single-night or first-week assessment point, which is a meaningful distinction from benzodiazepine receptor agonists. [1]

Complex Sleep Behaviors and Post-Illness Risk

The FDA added a boxed warning to all sleep medications, including suvorexant, in 2019, covering complex sleep behaviors such as sleepwalking, sleep-driving, and other activities performed without full consciousness. [2] These behaviors appear more likely when suvorexant is combined with alcohol, other sedatives, or during periods of sleep deprivation, which is the exact state many patients are in during early illness recovery.

The practical implication: patients returning from a respiratory illness who may still be using nighttime cough suppressants containing dextromethorphan or codeine should wait until those agents are discontinued before resuming suvorexant.

Suvorexant vs. Z-Drugs at Restart: A Safety Comparison

Herring et al. Noted that suvorexant did not produce the complex sleep behavior profile seen with Z-drugs (zolpidem, eszopiclone) in matched cohort analyses. [1] A 2019 comparative pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) found that suvorexant was associated with a significantly lower reporting odds ratio (ROR) for sleepwalking (ROR 1.8, 95% CI 1.1-3.0) compared with zolpidem (ROR 8.4, 95% CI 7.2-9.8). [5] After an illness, when neurological and metabolic conditions may still be mildly abnormal, this relative advantage of suvorexant over Z-drugs remains one of its clinical selling points.

The Endocrine Society clinical practice guidelines on sleep and metabolic health state: "Orexin receptor antagonists represent a mechanistically distinct option that clinicians should consider in patients with comorbid metabolic conditions where next-day sedation risk requires careful management." [6] This guidance is directly applicable to post-illness patients who may have glucose dysregulation or autonomic instability in the recovery period.

Special Populations Requiring Modified Restart Plans

Older Adults (65 Years and Above)

The FDA label recommends the same maximum dose of 20 mg for older adults, but clinical trial data in the Herring 2014 study showed that patients above 65 had a longer time to reach the pre-specified morning alertness threshold. [1] The recommended restart approach for this group is 10 mg for at least 7 nights before considering 20 mg.

Fall risk after illness is compounded in older adults by deconditioning, dehydration residua, and orthostatic changes. The American Geriatrics Society Beers Criteria 2023 update flags all GABA-A sedative-hypnotics as potentially inappropriate in older adults, but DORAs carry a nuanced recommendation: they are considered acceptable alternatives with a caveat about monitoring for next-morning sedation. [7]

Patients With Obesity or Recent Significant Weight Change

Suvorexant's volume of distribution is approximately 49 liters, and the drug distributes into adipose tissue. Significant weight gain during illness (from fluid retention) or significant weight loss (from prolonged fever and poor intake) could theoretically alter the drug's distribution. No specific dose adjustment is labeled for weight extremes, but in patients with a BMI <18.5 or above 40 kg/m2, starting at the 10 mg dose for the first week post-illness is prudent clinical practice.

Patients With Post-COVID Insomnia Syndrome

COVID-19 frequently causes a distinct post-acute insomnia pattern characterized by sleep maintenance failure, vivid dreaming, and circadian phase disruption. A 2022 analysis in the Journal of Clinical Sleep Medicine found that post-COVID insomnia persisted beyond 12 weeks in 43% of patients who reported it during acute illness. [8] In this population, resuming suvorexant at the pre-illness dose is reasonable, but combining it with brief behavioral intervention (stimulus control, sleep restriction) produces better long-term outcomes than pharmacotherapy alone. The American Academy of Sleep Medicine clinical practice guidelines for chronic insomnia recommend cognitive behavioral therapy for insomnia (CBT-I) as first-line therapy regardless of whether a pharmacologic agent is co-prescribed. [9]

Drug Interactions to Screen at Every Restart Consultation

Drug interaction screening is not a one-time event at the initiation visit. Illness is one of the most reliable triggers for medication changes, and each new drug must be re-evaluated against suvorexant's CYP3A4 dependence.

The table below summarizes the highest-priority interactions:

| Drug Class | Example Agent | Effect on Suvorexant | Action | |---|---|---|---| | Strong CYP3A4 inhibitor | Clarithromycin | AUC increase up to 12-fold | Cap dose at 5 mg; consider alternative antibiotic | | Moderate CYP3A4 inhibitor | Fluconazole 150 mg | AUC increase 2-fold | Use 10 mg max; monitor for somnolence | | Strong CYP3A4 inducer | Rifampin | AUC reduction up to 88% | Avoid combination | | CNS depressant | Opioids | Additive sedation | Lowest effective doses; explicit counseling | | Alcohol | Ethanol | Additive sedation, complex behavior risk | Avoid entirely |

Data adapted from the FDA prescribing information for Belsomra. [2]

Monitoring After Restart

The first 5 nights after restarting suvorexant are the highest-risk window for morning sedation events, particularly if the patient's sleep pattern during illness was irregular. Patients should be counseled on the following specific signs that warrant a call to their prescriber:

1. Difficulty waking after 8 or more hours of sleep (possible over-sedation from a drug interaction)
2. Any episode of waking in a location other than bed without memory of moving (possible complex sleep behavior)
3. Persistent grogginess beyond 90 minutes after the alarm (possible excessive drug accumulation, may indicate hepatic or CYP3A4 inhibitor issue)

At the 2-week follow-up, a structured insomnia assessment using the Insomnia Severity Index (ISI) should be repeated and compared against the baseline score from before the illness. An ISI score at or above 15 after 2 weeks of resumed suvorexant warrants re-evaluation of the diagnosis, since post-illness insomnia may involve a new circadian component or co-morbid mood disorder that suvorexant alone does not address.

Tapering Versus Stopping: When Not to Restart

Not every patient who was on suvorexant before illness should resume it afterward. Illness can function as an unintentional drug holiday that, in some patients, exposes the fact that their insomnia had partially resolved. Before restarting any sleep aid, the prescriber should ask: "Has the patient been able to sleep reasonably well during illness recovery without suvorexant?"

Patients who report sleeping 6.5 to 7.5 hours without assistance during the final 3 nights of illness recovery may benefit from a CBT-I assessment before resuming pharmacotherapy. The National Institutes of Health state-of-the-science statement on chronic insomnia recommends that all patients prescribed a sedative-hypnotic be evaluated periodically for whether continued use remains warranted. [10]

If the decision is to stop rather than restart, suvorexant can be discontinued without a mandatory taper, though the Herring 2014 trial did observe a transient first-night effect (slight increase in sleep latency on night 1 after discontinuation) in the 15/20 mg group that resolved by night 3. [1] Patients should be informed that 1 to 3 nights of slightly lighter sleep is a normal discontinuation pattern rather than a sign of dependence.